NEUROCRINE BIOSCIENCES INC Amortization of Debt Issuance Costs and Discounts
NEUROCRINE BIOSCIENCES INC (NBIX) reported Amortization of Debt Issuance Costs and Discounts of $700.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2024-02-09
- NEUROCRINE BIOSCIENCES INC amortization of debt issuance costs and discounts for the quarter ending 2023-12-31 was $100.00K, a 50.00% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC amortization of debt issuance costs and discounts for the quarter ending 2023-09-30 was $200.00K, a 0.00% change year-over-year.
- NEUROCRINE BIOSCIENCES INC amortization of debt issuance costs and discounts for the quarter ending 2023-06-30 was $200.00K, a 50.00% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC amortization of debt issuance costs and discounts for the quarter ending 2023-03-31 was $200.00K, a 50.00% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC amortization of debt issuance costs and discounts for fiscal 2023 was $700.00K, a 41.67% decline from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC amortization of debt issuance costs and discounts for fiscal 2022 was $1.20M, a 93.06% decline from fiscal 2021.
- NEUROCRINE BIOSCIENCES INC amortization of debt issuance costs and discounts for fiscal 2021 was $17.30M, a 19.16% decline from fiscal 2020.
- NEUROCRINE BIOSCIENCES INC amortization of debt issuance costs and discounts for fiscal 2020 was $21.40M.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2023-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $300.00K derived: sum of 2 quarters · filed 2024-02-09 | $500.00K derived: sum of 3 quarters · filed 2024-02-09 | $700.00K 10-K · filed 2024-02-09 |
| 2023-09-30 | $200.00K 10-Q · filed 2023-10-31 | $400.00K derived: sum of 2 quarters · filed 2023-10-31 | $600.00K 10-Q · filed 2023-10-31 | $800.00K derived: sum of 4 quarters · filed 2024-02-09 |
| 2023-06-30 | $200.00K 10-Q · filed 2023-08-01 | $400.00K 10-Q · filed 2023-08-01 | $600.00K derived: sum of 3 quarters · filed 2024-02-09 | $800.00K derived: sum of 4 quarters · filed 2024-02-09 |
| 2023-03-31 | $200.00K 10-Q · filed 2023-05-03 | $400.00K derived: sum of 2 quarters · filed 2024-02-09 | $600.00K derived: sum of 3 quarters · filed 2024-02-09 | $1.00M derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $400.00K derived: sum of 2 quarters · filed 2024-02-09 | $800.00K derived: sum of 3 quarters · filed 2024-02-09 | $1.20M 10-K · filed 2024-02-09 |
| 2022-09-30 | $200.00K 10-Q · filed 2023-10-31 | $600.00K derived: sum of 2 quarters · filed 2023-10-31 | $1.00M 10-Q · filed 2023-10-31 | $5.40M derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-06-30 | $400.00K 10-Q · filed 2023-08-01 | $800.00K 10-Q · filed 2023-08-01 | $5.20M derived: sum of 3 quarters · filed 2024-02-09 | $9.60M derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-03-31 | $400.00K 10-Q · filed 2023-05-03 | $4.80M derived: sum of 2 quarters · filed 2024-02-09 | $9.20M derived: sum of 3 quarters · filed 2024-02-09 | $13.50M derived: sum of 4 quarters · filed 2024-02-09 |
| 2021-12-31 | $4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $8.80M derived: sum of 2 quarters · filed 2024-02-09 | $13.10M derived: sum of 3 quarters · filed 2024-02-09 | $17.30M 10-K · filed 2024-02-09 |
| 2021-09-30 | $4.40M 10-Q · filed 2022-11-01 | $8.70M derived: sum of 2 quarters · filed 2022-11-01 | $12.90M 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $4.30M 10-Q · filed 2022-08-04 | $8.50M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $4.20M 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | $21.40M 10-K · filed 2023-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |